“Tyrosine Kinase Inhibitors for EGFR- and ALK-Mutated Non-Small Cell Lung Cancer”. ADMET and DMPK, vol. 4, no. 3, Oct. 2016, pp. 186-11, https://doi.org/10.5599/admet.4.3.337.